These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20721787)

  • 1. Mining pharmacovigilance data using Bayesian logistic regression with James-Stein type shrinkage estimation.
    An L; Fung KY; Krewski D
    J Biopharm Stat; 2010 Sep; 20(5):998-1012. PubMed ID: 20721787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A knowledge based approach for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Stud Health Technol Inform; 2004; 107(Pt 1):626-30. PubMed ID: 15360888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker.
    Berlin C; Blanch C; Lewis DJ; Maladorno DD; Michel C; Petrin M; Sarp S; Close P
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):622-30. PubMed ID: 21994119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases.
    Johnson K; Guo C; Gosink M; Wang V; Hauben M
    Bioinformatics; 2012 Dec; 28(23):3123-30. PubMed ID: 23064001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A shrinkage-based comparative assessment of observed-to-expected disproportionality measures.
    Gipson G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):589-96. PubMed ID: 22290739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A qualitative approach to signal mining in pharmacovigilance using formal concept analysis.
    Lillo-Le Louët A; Toussaint Y; Villerd J
    Stud Health Technol Inform; 2010; 160(Pt 2):969-73. PubMed ID: 20841828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
    Ahmed I; Haramburu F; Fourrier-Réglat A; Thiessard F; Kreft-Jais C; Miremont-Salamé G; Bégaud B; Tubert-Bitter P
    Stat Med; 2009 Jun; 28(13):1774-92. PubMed ID: 19360795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.
    Bate A; Lindquist M; Orre R; Edwards IR; Meyboom RH
    Eur J Clin Pharmacol; 2002 Oct; 58(7):483-90. PubMed ID: 12389072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L; Zalkikar J; Tiwari RC
    J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety data mining with a tree-based scan statistic.
    Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class-imbalanced subsampling lasso algorithm for discovering adverse drug reactions.
    Ahmed I; Pariente A; Tubert-Bitter P
    Stat Methods Med Res; 2018 Mar; 27(3):785-797. PubMed ID: 27114328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data mining and statistically guided clinical review of adverse event data in clinical trials.
    Southworth H; O'Connell M
    J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical methods for active pharmacovigilance, with applications to diabetes drugs.
    Zhuo L; Farrell PJ; McNair D; Krewski D
    J Biopharm Stat; 2014; 24(4):856-73. PubMed ID: 24697529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information.
    Ghosh P; Dewanji A
    Stat Med; 2011 Jul; 30(16):2040-55. PubMed ID: 21544847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian nonstationary autoregressive models for biomedical signal analysis.
    Cassidy MJ; Penny WD
    IEEE Trans Biomed Eng; 2002 Oct; 49(10):1142-52. PubMed ID: 12374338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.